Long-term investment in UK life sciences is not guaranteed, but it could be

6 September 2023
jean-christophe-tellier

Jean-Christophe Tellier, chief executive of Belgium's largest biotech, UCB, provides an op-ed on the UK life sciences.

In the context of ongoing discussions between government and industry over the UK's drug pricing framework, Dr Tellier argues that long-term investment is possible, as long as the right operational and commercial environment exists.

The UK is an attractive place to conduct life science research and development (R&D). However, we must caveat this statement with the words, ‘for now’.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical